Crispr Theraptc (NASDAQ:CRSP) Director Kurt Von Emster sold 35,473 shares of the business’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $18.63, for a total transaction of $660,861.99. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Kurt Von Emster also recently made the following trade(s):
- On Friday, August 4th, Kurt Von Emster sold 50,477 shares of Crispr Theraptc stock. The stock was sold at an average price of $17.81, for a total transaction of $898,995.37.
- On Tuesday, August 1st, Kurt Von Emster sold 5,512 shares of Crispr Theraptc stock. The stock was sold at an average price of $17.51, for a total transaction of $96,515.12.
- On Friday, July 28th, Kurt Von Emster sold 41,312 shares of Crispr Theraptc stock. The stock was sold at an average price of $17.63, for a total transaction of $728,330.56.
- On Wednesday, July 26th, Kurt Von Emster sold 32,930 shares of Crispr Theraptc stock. The stock was sold at an average price of $17.60, for a total transaction of $579,568.00.
- On Friday, July 14th, Kurt Von Emster sold 69,859 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.84, for a total transaction of $1,176,425.56.
- On Wednesday, July 12th, Kurt Von Emster sold 31,992 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.56, for a total transaction of $529,787.52.
- On Wednesday, July 5th, Kurt Von Emster sold 4,254 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.26, for a total transaction of $69,170.04.
- On Thursday, June 29th, Kurt Von Emster sold 43,202 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.90, for a total transaction of $730,113.80.
- On Tuesday, June 27th, Kurt Von Emster sold 81,435 shares of Crispr Theraptc stock. The stock was sold at an average price of $17.08, for a total transaction of $1,390,909.80.
- On Friday, June 23rd, Kurt Von Emster sold 32,368 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.23, for a total transaction of $525,332.64.
Shares of Crispr Theraptc (CRSP) opened at 17.80 on Friday. Crispr Theraptc has a 52 week low of $11.63 and a 52 week high of $25.00. The company’s market cap is $711.95 million. The company has a 50 day moving average of $17.00 and a 200 day moving average of $17.49.
Crispr Theraptc (NASDAQ:CRSP) last released its earnings results on Thursday, May 11th. The company reported ($0.54) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.06. The business had revenue of $2.70 million for the quarter. On average, analysts expect that Crispr Theraptc will post ($2.48) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Kurt Von Emster Sells 35,473 Shares of Crispr Theraptc (NASDAQ:CRSP) Stock” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/08/11/kurt-von-emster-sells-35473-shares-of-crispr-theraptc-nasdaqcrsp-stock.html.
CRSP has been the topic of a number of research reports. SunTrust Banks, Inc. initiated coverage on shares of Crispr Theraptc in a research note on Thursday, July 13th. They set a “hold” rating and a $16.00 target price on the stock. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research note on Tuesday, July 18th. Finally, Cann started coverage on shares of Crispr Theraptc in a research note on Monday, July 17th. They issued a “market perform” rating on the stock. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $21.92.
A number of large investors have recently made changes to their positions in CRSP. Wellington Management Group LLP raised its stake in shares of Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock worth $16,272,000 after buying an additional 3,070 shares during the period. IHT Wealth Management LLC purchased a new stake in shares of Crispr Theraptc during the first quarter worth about $110,000. Wells Fargo & Company MN raised its stake in shares of Crispr Theraptc by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after buying an additional 6,560 shares during the period. Monashee Investment Management LLC raised its stake in shares of Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares during the period. Finally, Paulson & CO. Inc. purchased a new stake in shares of Crispr Theraptc during the first quarter worth about $1,099,000. 24.08% of the stock is currently owned by institutional investors and hedge funds.
Crispr Theraptc Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.
